A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso.
BACKGROUND
Intermittent preventive treatment with sulphadoxine-pyrimethamine for pregnant women (IPTp-SP) is currently being scaled up in many countries in sub-Saharan Africa. Despite high antenatal clinic (ANC) attendance, coverage with the required two doses of SP remains low. The study investigated whether a targeted community-based promotion campaign to increase ANC attendance and SP uptake could effectively improve pregnancy outcomes in the community.


METHODS
Between 2004 and 2006 twelve health centres in Boromo Health District, Burkina Faso were involved in this study. Four were strategically assigned to community promotion in addition to IPTp-SP (Intervention A) and eight were randomly allocated to either IPTp-SP (Intervention B) or weekly chloroquine (Control). Primi- and secundigravidae were enrolled at village level and thick films and packed cell volume (PCV) taken at 32 weeks gestation and at delivery. Placental smears were prepared and newborns weighed. Primary outcomes were peripheral parasitaemia during pregnancy and at delivery, placental malaria, maternal anaemia, mean and low birth weight. Secondary outcomes were the proportion of women with > or = 3 ANC visits and > or = 2 doses of SP. Intervention groups were compared using logistic and linear regression with linearized variance estimations to correct for the cluster-randomized design.


RESULTS
SP uptake (> or = 2 doses) was higher with (Intervention A: 70%) than without promotion (Intervention B: 49%) (OR 2.45 95%CI 1.25-4.82 p = 0.014). Peripheral (33.3%) and placental (30.3%) parasite rates were significantly higher in the control arm compared to Intervention B (peripheral: 20.1% OR 0.50 95%CI 0.37-0.69 p = 0.001; placental: 20.5% OR 0.59 95%CI 0.44-0.78 p = 0.002) but did not differ between Intervention A (17.4%; 18.1%) and Intervention B (20.1; 20.5%) (peripheral: OR 0.84 95%CI 0.60-1.18 p = 0.280; placental: OR 0.86 95%CI 0.58-1.29 p = 0.430). Mean PCV and birth weight and prevalence of anaemia and low birth weight did not differ between study arms.


CONCLUSIONS
The promotional campaign resulted in a major increase in IPTp-coverage, with two thirds of women at delivery having received > or = 2 SP. Despite lower prevalence of malaria infection this did not translate into a significant difference in maternal anaemia or birth weight. This data provides evidence that, as with immunization programmes, extremely high coverage is essential for effectiveness. This critical threshold of coverage needs to be defined, possibly on a regional basis.
Gies
Sabine
S
Epidemiology and Control of Parasitic Diseases Unit, Department of Parasitology, Institute of Tropical Medicine, Antwerp, Belgium. sgies@itg.be
Coulibaly
Sheick Oumar
SO
Ouattara
Florence Tiemegna
FT
Ky
Clotilde
C
Brabin
Bernard John
BJ
D'Alessandro
Umberto
U
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002050:Burkina Faso; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006293:Health Promotion; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D037841:Pregnant People; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine
Acta Trop. 2008 Jan;105(1):81-6
17904509
J Infect Dis. 2007 Dec 1;196(11):1574-6
18008239
Cochrane Database Syst Rev. 2006;(4):CD000169
17054128
Am J Trop Med Hyg. 2006 Aug;75(2):205-11
16896120
Malar J. 2007;6:144
17996048
Lancet Infect Dis. 2007 Feb;7(2):145-55
17251085
Malar J. 2007;6:27
17341298
Demography. 2001 Feb;38(1):115-32
11227840
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):28-35
11425175
Bull World Health Organ. 2002;80(9):721-7
12378290
Trop Med Int Health. 2002 Nov;7(11):925-30
12390597
Lancet. 2003 Feb 15;361(9357):561-6
12598141
J Clin Microbiol. 2003 Apr;41(4):1370-4
12682116
J Midwifery Womens Health. 2003 Jul-Aug;48(4):268-72
12867911
Bull World Health Organ. 1983;61(6):1005-16
6370484
N Engl J Med. 1985 Jan 10;312(2):82-90
3880598
World Health Organ Tech Rep Ser. 1986;735:1-104
3094255
Ann Trop Med Parasitol. 1987 Apr;81 Suppl 1:77-82
3689040
Trop Geogr Med. 1993;45(2):49-55
8511810
Am J Trop Med Hyg. 1994 Nov;51(5):515-22
7985742
Am J Trop Med Hyg. 1996;55(1 Suppl):2-7
8702033
Am J Trop Med Hyg. 1996;55(1 Suppl):17-23
8702032
Am J Trop Med Hyg. 1998 Nov;59(5):813-22
9840604
Lancet. 1999 Feb 20;353(9153):632-6
10030329
J Infect Dis. 2005 Jan 1;191(1):109-16
15593011
Lancet. 2005 Mar 19-25;365(9464):1087-98
15781104
Trop Med Int Health. 2006 Apr;11(4):409-18
16553924
Malar J. 2006;5:49
16776817
Am J Trop Med Hyg. 2007 Apr;76(4):608-13
17426157
Trop Med Int Health. 2007 Apr;12(4):519-31
17445143
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):56-60
18165475